HSTM insider sale: EVP Kevin O'Hara sold 2,000 shares at $27.97
HealthStream Inc. executive Kevin P. O'Hara reported the sale of 2,000 shares of the company's common stock on 08/27/2025, at a weighted average price of $27.9679 per share (individual trades ranged from $27.79 to $28.10).
Rhea-AI Filing Summary
HealthStream Inc. executive Kevin P. O'Hara reported the sale of 2,000 shares of the company's common stock on 08/27/2025, at a weighted average price of $27.9679 per share (individual trades ranged from $27.79 to $28.10). After the sale, Mr. O'Hara beneficially owned 17,137 shares. The Form 4 identifies Mr. O'Hara as an Executive Vice President and officer of the issuer and shows the filing was signed on 08/27/2025. The disclosure includes an agreement to provide trade-level detail on request and contains no derivative transactions or other securities reported on this form.
Positive
- Timely SEC disclosure filed and signed, documenting the insider transaction and offering to provide trade-level details on request
- No derivative activity reported on this Form 4, limiting complexity of the disclosure
Negative
- Insider sale of 2,000 shares on 08/27/2025, reducing beneficial ownership to 17,137 shares
- Weighted average price reported rather than trade-level prices (individual trades ranged $27.79–$28.10), which requires request for full detail
Insights
TL;DR Insider sale of 2,000 HSTM shares by an executive; routine reporting with no derivatives disclosed.
Kevin P. O'Hara, an Executive Vice President and reporting person, disposed of 2,000 shares on 08/27/2025 at a weighted average price of $27.9679, reducing his beneficial ownership to 17,137 shares. The filing follows Section 16 reporting requirements and includes an explanatory note that the reported price is a weighted average across multiple trades between $27.79 and $28.10. There are no option exercises, grants, or other derivative transactions reported on this Form 4. This appears to be a standard insider sale disclosure without additional material events.
TL;DR Timely, compliant Form 4 filing documenting an executive sale; no governance red flags present in the disclosure.
The report is signed and dated 08/27/2025 and explicitly states the reporting person's role as Executive Vice President. The explanatory footnote commits to providing trade-level details upon request, which supports transparency. No indications of related-party transactions, plan-based sales (no 10b5-1 box checked), or concurrent derivative activity are present. From a governance perspective, the document meets basic SEC disclosure standards and contains no immediate compliance concerns.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock Holding | 2,000 | $27.9679 | $56K |
Footnotes (1)
- F1. This transaction was executed in multiple trades at prices ranging from $27.79 to $28.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
FAQ
What did Kevin P. O'Hara report in the HSTM Form 4?
Does the Form 4 show any option exercises or derivative transactions for HSTM?
What is Kevin P. O'Hara's role at HealthStream as stated on the form?
Is additional trade detail available for the reported HSTM sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.